Scientific Advisory Board

Scientific Advisory Board

Larry Wheeler

Chairman of Scientific Advisory Board | Ph.D.

Dr. Wheeler serves as the Chairman of Allgenesis’ Scientific Advisory Board, where he provides insight in the development of Allgenesis’ compounds. Dr. Wheeler was involved in Discovery research at Allergan for 32 years. He currently is a Research Professor of Ophthalmology at the Moran Eye Center. Areas of interest are Ophthalmic drug discovery and development; Age-related Macular Degeneration; Pharmacology of glaucoma, Dry Eye and neuroprotection.

Dr. Wheeler was Senior Vice-President of Biological Sciences Discovery Research at Allergan, Inc until April 2014. He is a member of the American Society for Pharmacology and Experimental Therapeutics and the Association for Research in Vision and Ophthalmology. He has authored book chapters and over 110 papers in peer-reviewed journals and awarded over 60 patents in the areas of neuroprotection, pharmacology of alpha-2 receptors, apoptosis and NMDA antagonists. Other research areas are the pharmacology of retina, glaucoma, dry eye, ocular inflammation and neurotoxins.

Dr. Wheeler holds a B.S. degree from the University of Redlands and an M.S. and Ph.D. from the Department of Pharmacology, Loma Linda School of Medicine. Dr. Wheeler performed postdoctoral research in the Department of Pharmacology at Harvard Medical School and served as Assistant Professor in the Department of Pharmacology at the University of California at Los Angeles and Research Scientist at the Wadsworth VA Hospital.

Scientific Advisory Board

Janet Cheetham

Scientific Advisory Board Member | Pharm.D.

Dr. Cheetham serves as a Scientific Advisory Board Member. She has more than 30 years of industry experience in ophthalmology drug development including retina, glaucoma, and anterior segment. She currently consults for Foundation Fighting Blindness and both private and public companies. Her last position at Allergan was Vice President, Clinical Development in the Retina Therapeutic Area. She was the project team leader and clinical lead for several compounds from pre-IND to market launch, including anti-VEGF DARPin/abicipar, Dual DARPin, brimonidine DDS, beclomethasone, triamcinolone, memantine and more. The patient populations participating in these studies included neovascular age-related macular degeneration, geographic atrophy, retinal vein occlusion, diabetic macular edema, retinal detachment, non-arteritic ischemic optic neuropathy, retinitis pigmentosa, and glaucomatous optic neuropathy. She was responsible for external collaborations and internal programs.

Dr. Cheetham also served as Vice President of Clinical Operations, growing the group from 12 employees to more than 100 before she returned to the role of project team leader. Dr. Cheetham is a pharmacist by training, earning her Doctor of Pharmacy from University of Southern California. She completed a post-doc fellowship at Doheny Eye Institute in Los Angeles in conjunction with the University of Southern California.

Scientific Advisory Board

Sunil Patel

Scientific Advisory Board Member | M.D., Ph.D.

Dr. Patel serves as a Scientific Advisory Board member. He is a board-certified ophthalmologist and has been a practicing Vitreoretinal Surgeon for the past 20+ years in the West Texas area. He is currently the Managing Partner at Ophthalmology Specialist of Texas, PLLC and Abilene Surgery Center; the President of Integrated Clinical Research, LLC; and a Staff Investigator for Strategic Clinical Research Group.

Dr. Patel is a world-renowned retinal specialist and has participated as a principal investigator in various retinal clinical trials for leading pharmaceutical companies such as Allergan, Boehringer Ingelheim, Genentech, Graybug, Kodiak, Novartis, Opthea, Chengdu Kanghong, and many others. His area of interests include the applications of novel molecules in the management of retinal degenerative diseases and innovative surgical therapies for the management of retinal diseases such as wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

Dr. Patel graduated magna cum laude from UCLA’s Department of Chemistry and Biochemistry. He received his M.D. from the University of Texas Southwestern Medical School, where he was the recipient of the Southwestern Medical Foundation Scholarship, and his Ph.D. from the University of Texas Southwestern Graduate School of Biomedical Sciences. Upon completing an internship in internal medicine at the Presbyterian Hospital of Dallas, Dr. Patel completed his residency in ophthalmology at the Doheny Eye Institute-Los Angeles County Hospital at the University of Southern California. His fellowship training was in medical retina, surgical retina and uveitis at Los Angeles County Hospital-USC.